We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
By Sabela Ojea
Shares in Silence Therapeutics PLC on Wednesday rose after it agreed a $60 million cash payment and $20 million equity investment from AstraZeneca.
The U.K. biotechnology company said its collaboration with AstraZeneca will focus on small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases. The companies anticipate beginning work on five targets within the first three years of the collaboration, with AstraZeneca having the option to extend the agreeemnt to a further five targets.
AstraZeneca will pay Silence an option fee of $10 million for each selected target and thereafter for each target selected Silence will be eligible for up to $140 million in development milestones and $250 million in commercialization milestones, as well as tiered royalties on net sales.
Silence Therapeutics said its SLN360 product for the potential treatment of cardiovascular disease is now its priority "as a result of the high and prevalent unmet medical need and the excellent preclinical profile."
It also said that it plans to submit and investigation new drug application with the U.S. Food and Drug Administration in 2020 and start a first in man study to generate interim data around the middle of 2021.
Shares at 0826 GMT were up 129 pence, or 32%, at 535.00 pence.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
March 25, 2020 04:51 ET (08:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions